|
[摘要]:This perspective is the last in a series of papers discussing drugs dropped from clinical development in 2006. Specifically, this paper focuses on the 16 drugs discontinued for the treatment of cancer, the largest area of pharma R&D. This was based on a search of the Pharmaprojects database for drugs reaching Phase I - III clinical trials. |
|